Zydus Lifesciences Ltd.Revenue +22%, EBITDA Margin 24.1%

Zydus Lifesciences reported Q1 FY27 consolidated revenue of ₹8,020 Cr, up 22%, with EBITDA of ₹1,930 Cr at a 24.1% margin and net profit of ₹940 Cr; net debt to EBITDA was 0.7x.

India branded formulations grew 20%, international formulations 34% to ₹970 Cr, and consumer wellness 67% to ₹1,430 Cr including the Comfort Click portfolio, while North America revenue was ₹3,100 Cr, up 5% sequentially. In the US the company launched its first biosimilar, Nufymco (ranibizumab), completed the Assertio acquisition and filed Saroglitazar, which received FDA priority review for primary biliary cholangitis, with a US launch planned for April 2027.

Gross margin dipped on Mirabegron settlement costs. Management kept its FY27 guidance of strong double-digit growth, a 24% EBITDA margin and capex of ₹1,500 Cr to ₹1,600 Cr, and said Saro spending rises in the second half. It targets branded products above two-thirds of revenue in the medium term and an EBITDA margin of 28% to 30% over five years.